2018
DOI: 10.1080/20008198.2018.1458568
|View full text |Cite
|
Sign up to set email alerts
|

Moving forward in treatment of posttraumatic stress disorder: innovations to exposure-based therapy

Abstract: The field of treatment of posttraumatic stress disorder (PTSD) has been a pacesetter for the changing face of psychotherapy, as is illustrated in the introduction of Virtual Reality Exposure Therapy. This paper outlines a novel approach that builds on a cognitive-motor interaction in a virtual interactive environment. It is based on the theory of memory reconsolidation and the embodiment of cognition. The framework we envision allows the patient to 'step into the past' by using forward motion as an essential i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
30
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
6
2

Relationship

1
7

Authors

Journals

citations
Cited by 24 publications
(30 citation statements)
references
References 14 publications
(18 reference statements)
0
30
0
Order By: Relevance
“…The last 10 years have seen the rapid proliferation of these new technologies (Olff, 2015b) and the trauma field has been keen to explore this new world, as often reported in this journal. Research into the use of virtual reality has continued to develop (Kothgassner et al, 2019;Rizzo & Shilling, 2017), evolving in recent years to incorporate cognitive-motor components as an innovative element in a personalized virtual interactive intervention, aimed at individuals with treatment-resistant PTSD (Nijdam & Vermetten, 2018).…”
Section: New Technologies and Trauma Interventionsmentioning
confidence: 99%
“…The last 10 years have seen the rapid proliferation of these new technologies (Olff, 2015b) and the trauma field has been keen to explore this new world, as often reported in this journal. Research into the use of virtual reality has continued to develop (Kothgassner et al, 2019;Rizzo & Shilling, 2017), evolving in recent years to incorporate cognitive-motor components as an innovative element in a personalized virtual interactive intervention, aimed at individuals with treatment-resistant PTSD (Nijdam & Vermetten, 2018).…”
Section: New Technologies and Trauma Interventionsmentioning
confidence: 99%
“…In a first proof of concept veterans with treatment-resistant PTSD (TR-PTSD) positively evaluated the acceptability of 3MDR [29]. Preliminary findings suggested that 3MDR could lead to clinically meaningful changes, which for some patients were not experienced until 4-6 weeks after the intervention [18,29,30].…”
Section: Introductionmentioning
confidence: 99%
“…The current study aimed to test the efficacy of 3MDR for veterans with TR-PTSD in a randomized controlled trial (RCT) comparing 3MDR to a non-specific treatment component control group (NTCC), consisting of treatment without trauma-focused elements. Based on the literature reviewed above, we expected the combined arsenal of therapeutic techniques in 3MDR to improve treatment outcomes for veterans who did not respond to prior current evidence-based treatment, and we expected that this effect would occur a few weeks after the 3MDR intervention and increase over time [18,30]. Therefore, our primary hypothesis was that 3MDR would significantly decrease PTSD symptoms at the end point, 16 weeks after start of treatment, as compared to the control intervention.…”
Section: Introductionmentioning
confidence: 99%
“…Of the 18 studies, nine (50%) (Difede et al, 2013;Rothbaum et al, 2014;Reger et al, 2016;Beidel et al, 2017a;McLay et al, 2017;Maples-Keller et al, 2018;Van't Wout et al, 2018;Bisson et al, 2020;Van Gelderen et al, 2020) were RCTs with a total of 483 patients (317 received VR treatment, 100 received an active treatment and 66 allocated to waitlist). Six (33.3%) (Vermetten et al, 2013;Arens, 2014;Kengne et al, 2018;Menelas et al, 2018;Nijdam and Vermetten, 2018;Van Gelderen et al, 2018) were case studies examined a total of 10 patients and three (16.6%) (Beidel et al, 2017b;Jetly et al, 2017;Loucks et al, 2018) were non-randomized single-arm trials subsumed to pilot studies with a total of 116 patients.…”
Section: General Overviewmentioning
confidence: 99%